Document:

Disclosure Letter to Securities Purchase Agreement

 EXHIBIT 10.51 
 ARTHROCARE CORPORATION 
 7500 Rialto Boulevard

 Building Two, Suite 100 
 Austin, Texas 78735 
 August 14, 2009 
 OEP AC Holdings, LLC 
 320 Park
Avenue, 18th Floor 
 New York, New York 10022 
 Re:  Disclosure Letter 
 Ladies and Gentlemen: 
 Reference is made to the Securities Purchase Agreement (the “Agreement”), entered into as of August 14, 2009, by and
between ArthroCare Corporation, a Delaware corporation (the “Company”), and OEP AC Holdings, LLC, a Delaware limited liability company. This letter (the “Disclosure Letter”) is being provided pursuant to
Section 2 of the Agreement and the information and disclosures contained herein are intended only to qualify and limit the representations and warranties contained in the Agreement. Capitalized terms used herein and not otherwise defined herein
shall have the meanings assigned to such terms in the Agreement. 
 The headings and descriptions used herein are for
convenience of reference only and are not intended to and do not alter or amend the meaning of any provision of the Agreement. Furthermore, disclosure of any item in this Disclosure Letter by reference to any particular Section or Subsection of the
Agreement shall be deemed to constitute disclosure with respect to any other Section or Subsection of the Agreement if the relevance of such disclosure to such other Section or Subsection is readily apparent from such disclosure or the context in
which such disclosure is made. This Disclosure Letter may include items or information which the Company is not required to disclose under the Agreement. Disclosure of such items or information does not necessarily mean that other matters of a
similar nature are required to be disclosed, but such disclosure shall not affect the scope of the disclosure obligation under the Agreement. No disclosure in this Disclosure Letter relating to any possible breach or violation of any agreement, law
or regulation shall be construed as an admission that any such breach or violation exists or has actually occurred. 
 This
Disclosure Letter is qualified in its entirety by reference to the specific provisions of the Agreement. 
  

	
	Sincerely,
	
	ARTHROCARE CORPORATION

 Section 2.5 
 Litigation 
 Patent Litigation: 
 On November 14, 2007, the Company brought a lawsuit against Gyrus Medical Inc., Gyrus ENT L.L.C. and Gyrus ACMI Inc., Case
No. 1:07-CV-00729-SLR in the United States District Court for the District of Delaware, in which the Company seeks monetary damages and equitable relief for claims of patent infringement relating to U.S. Patent No. 5,697,882 (the
“’882 Patent). In the lawsuit, the Company alleges that the use of Gyrus’s “PlasmaCision” and “PlasmaKinetic” products and systems infringes the ’882 Patent. Gyrus seeks invalidation of the
Company’s patent based on alleged inequitable conduct and alleged prior art. This litigation is currently pending and the case has been set for trial beginning on November 2, 2009. 
 On May 5, 2008, Gyrus Medical Ltd. and Gyrus Group PLC commenced an arbitration proceeding against the Company. In its arbitration
notice, Gyrus alleged that, under the Settlement Agreement dated June 28, 1999 among the Company, Gyrus Medical Ltd., and Ethicon, Inc. and certain Ethicon affiliates (collectively, “Ethicon”), the Company had made
“material changes” to certain of its arthroscopy products — the Super TurboVac 90, the UltraVac, the Super MultiVac 50, the TurboVac 90XL and the MultiVac XL — and that those products infringed two Gyrus patents. Shortly
thereafter, on June 12, 2008, Ethicon and DePuy Mitek, Inc. joined the arbitration (Gyrus, Ethicon and DePuy Mitek collectively, the “Claimants”). The Company filed a counterclaim in the arbitration for breach of the
Settlement Agreement, alleging that Ethicon had not paid certain royalties when due under the Settlement Agreement. 
 On
June 10, 2009, the arbitration panel issued its interim decision and award. The panel ruled in favor of the Claimants on all issues, including the patent infringement and breach of contract claims, and against the Company on its breach of
contract counterclaim. The panel awarded the Claimants (i) $11.7 million for royalties on the patents due from April 2001 through February 2009, including pre-judgment interest of 10% through July 15, 2009; (ii) a 6.5% royalty
for all sales of the infringing products starting from March 1, 2009; and (iii) reasonable attorneys’ fees and costs, including the costs of the arbitration. The interim decision is attached as Exhibit B to the Petition referenced
below and attached hereto. 
 Gyrus and Ethicon submitted a fee request to the Company in the amount of $4.5 million. The
Company objected to the amount of this request and the parties informed the panel that they have failed to reach agreement on an attorneys fees amount and the panel has requested that both sides submit additional information to the Panel so that it
can issue a ruling on this dispute. 
 The Company has since filed a Petition to vacate or modify the Arbitration Award and to
stay the award. This petition was filed in the U.S. District Court for the Northern District of California. The petition is attached hereto. 

 Securities Litigation – Class Action and Derivative Suits: 
 On April 4, 2008, a securities fraud class action lawsuit was filed in Federal court in the Southern District of Florida against the
Company and certain of its former executive officers alleging improper revenue recognition practices by the Company and the improper reporting of such revenue in Commission filings and press releases (McIlvaine v. ArthroCare). 
 On July 25, 2008, a securities fraud class action lawsuit was filed in Federal court in the Western District of Texas against the
Company, a former director and certain of its current and former executive officers alleging improper revenue recognition practices by the Company and the improper reporting of such revenue in Commission filings and press releases (Strong v.
ArthroCare). 
 On August 7, 2008, a derivative action was filed in Federal court in the Southern District of Florida
against the Company and its then directors alleging breach of fiduciary duty based on the Company’s improper revenue recognition and its improper reporting of such revenue in Commission filings and press releases (Weil v. Baker).

 On October 20, 2008, a derivative action was filed in Texas State District Court against the Company, its then directors
and certain of its current and former executive officers alleging breach of fiduciary duty and unjust enrichment based on the Company’s improper revenue recognition and its improper reporting of such revenue in Commission filings and press
releases (Bocklet v. Baker). A stay has been granted in this action until October 1, 2009. 
 On March 4, 2009,
a derivative action was filed in Federal court in the Western District of Texas against the Company’s current directors, a former director, certain of its current and former executive officers and other employees and PriceWaterhouseCoopers, LLP
alleging (i) disgorgement under Section 304 of the Sarbanes-Oxley Act; (ii) violations of Section 10(b) of the Exchange Act; (iii) breach of fiduciary duty; (iv) abuse of control; (v) gross mismanagement of the
Company; (vi) waste of corporate assets; and (vii) unjust enrichment (King v. Baker). A joint motion to consolidate and motion to stay was filed on July 2, 2009. 
 On April 29, 2009, a derivative action was filed in Federal court in the Southern District of Florida against the Company’s
current directors and a former director alleging breach of fiduciary duty based on the Company’s improper revenue recognition and its improper reporting of such revenue in Commission filings and press releases (Barron v. Baker).

 As of the date hereof, the aforementioned cases have been consolidated into the following: 
 (i) In Re ArthroCare Corporation Securities Litigation, Case No. 1:08-cv-00574-SS (consolidated), U.S. District Court, Western
District of Texas. In this action, Plaintiffs allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder in a putative securities class action on behalf of certain purchasers of Company stock. Plaintiffs
allege that the Company and certain officers and directors violated federal securities laws by issuing false and misleading financial statements

 
and making material misrepresentations regarding the Company’s internal controls, business, and financial results. Additionally, certain shareholders have alleged derivative claims on behalf
of the Company that directors and officers of the Company breached their fiduciary duties to shareholders based on similar acts. The cases have been consolidated, and the Plaintiffs have been ordered to file an Amended Consolidated Complaint.

 (ii) In Re ArthroCare Corporation Derivative Litigation, Case No. D-1-GN-08-3484 (consolidated), Travis County
District Court. In this action, certain shareholders of the Company have alleged derivative claims on behalf of the Company that directors and officers of the Company breached their fiduciary duties to shareholders by failing to maintain adequate
financial controls over revenue recognition, allowing improper financial reporting, disseminating false financial statements, and engaging in insider trading. The case has been stayed until October 1, 2009 based on the consolidated federal
securities and derivative case. 
 Insurance-related Private Third-Party Claims: 
 The Company has been approached by The Allstate Corporation (“Allstate”) seeking a monetary settlement of potential claims
resulting from the former reimbursement practices of the Company and certain of its subsidiaries relating to the settlements of personal injury accident cases obtained from automotive insurance providers. As of the date hereof, no settlement
arrangement has been reached. 
 SEC Investigation: 
 On July 24, 2008, the Company received a letter from the U.S. Securities and Exchange Commission Division of Enforcement (“SEC”) stating that the SEC was conducting an informal
inquiry into accounting matters related to ArthroCare Corporation arising out of the Company’s announced restatement of financial results. On February 9, 2009, the SEC issued a formal order of investigation.
 DOJ Investigation: 
 The
United States Department of Justice (“DOJ”) is investigating certain activities of the Company including its past sales, accounting, and billing procedures in relation to, primarily, the operation of the Company’s spine
division. The DOJ is also reviewing the Company’s relationship with the Company’s subsidiary called DiscoCare, which was acquired in December of 2007, and its billing practices. The DOJ has requested the production of documents and other
information in relation to this investigation. 
 [*] 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

 Section 2.7 
 Tax 
 The Company’s 2007 US Consolidated Form 1120 has been held
by the Company and has not yet been filed pending resolution regarding the Company’s restatement of its financial results and its acquisition of DiscoCare, Inc. All anticipated tax liabilities have been remitted. 

 Section 2.8 
 Subsidiaries 
  

	 	•	 	 ArthroCare Canada Limited – Canada (British Columbia) 

  

	 	•	 	 ArthroCare Corporation Cayman Islands – Cayman Islands 

  

	 	•	 	 ArthroCare Costa Rica S.R.L. – Costa Rica 

  

	 	•	 	 ArthroCare Europe Aktiebolag – Sweden 

  

	 	•	 	 ArthroCare France SARL – France 

  

	 	•	 	 ArthroCare (Deutschland) AG – Germany 

  

	 	•	 	 ArthroCare (Hong Kong) Limited – Hong Kong 

  

	 	•	 	 ArthroCare Italy SRL – Italy 

  

	 	•	 	 ArthroCare Luxembourg S.à r.l. – Luxembourg 

  

	 	•	 	 ArthroCare Medical Corporation – Nevada 

  

	 	•	 	 ArthroCare (Australasia) Pty Ltd – Australia (New South Wales) 

  

	 	•	 	 ArthroCare Scandinavia ApS – Denmark 

  

	 	•	 	 ArthroCare UK Limited – United Kingdom 

  

	 	•	 	 Atlantech Medical Devices (UK) Limited – United Kingdom 

  

	 	•	 	 Atlantech medizinische Produkte Vertriebs-GmbH – Austria 

  

	 	•	 	 Device Reimbursement Services, Inc. – Nevada 

  

	 	•	 	 DiscoCare, Inc. – Delaware 

  

	 	•	 	 Medical Device Alliance Inc. – Nevada 

  

	 	•	 	 OC Acquisition Sub, LLC – California 

 Section 2.15 
 Agreements 
 Section 2.15(a). On January 13, 2006, the
Company entered into a five-year Revolving Credit Agreement with a syndicate of banks and Bank of America, N.A. acting as Administrative Agent. On December 18, 2007, the Company entered into the First Amendment to Credit Agreement, and on
November 26, 2008, the Company entered into the Second Amendment and Consent to the Credit Agreement between the Company and the lenders to the Credit Agreement and Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C
Issuer. The current available and outstanding amount under the Agreement is $45,000,000. In addition, the Company has a Standby Letter of Credit valued at 750,000 Euros, also under the Credit Agreement. This Standby Letter of Credit
relates to a VAT Guarantee associated with the establishment of the Company’s Belgium warehouse. 
 Section 2.15(b). None. 

 Section 2.22 
 Intellectual Property 
 Section 2.22(a). In an arbitration
proceeding conducted in March of 2009 against Claimants Ethicon, Inc. and Gyrus Group PLC, the arbitration panel entered an Interim Decision and Award on June 10, 2009 finding that certain of the Company’s “Arbitration Products”
infringe two patents held by Gyrus Group PLC and ordering the Company to pay $11,709,000 to Claimants in past damages, to pay Claimants reasonable costs and fees, and a 6.5% royalty on future sales of the “Arbitration Products.” The
Company and Claimants have submitted briefs to the panel related to the appropriate amount of Costs and Fees claimed by Claimants. The Arbitration panel’s final award is pending. On July 15, 2009, the Company filed a Petition to
Vacate the arbitration award in the United States District Court for the Northern District of California. The Motion to Vacate is pending. Please see attached 1999 Settlement Agreement, Arbitration Award and Motion to Vacate. Please also refer
to Section 2.5 and the subsection thereof entitled “Patent Litigation.” 
 Section 2.22(b). The Company has entered into
discussions with its joint partner for surgical fluid management (pump) systems, Medical Vision Research & Development AB (“Medical Vision”), concerning a previously signed Manufacturing, Development and Supply Agreement
between the Company and Medical Vision, and each party’s desire to unwind such agreement and to assign ownership of potential intellectual property rights resulting from cooperation between the parties. Please see the Manufacturing, Supply
and Distribution Agreement attached hereto for more information. 
 Section 2.22(c). In the Company’s enforcement proceedings
involving the ’882 Patent in the US District Court in Delaware against Gyrus Group PLC, Gyrus has alleged that the ’882 Patent is invalid over certain prior art and unenforceable due to alleged inequitable conduct. Please also refer
to Section 2.5 and the subsection thereof entitled “Patent Litigation.” 
 Section 2.22(e). The Company is currently
enforcing the ’882 Patent in the US District Court in Delaware against Gyrus Group PLC related to certain Gyrus products sold for use in Ear, Nose and Throat and general surgical procedures. Please also refer to Section 2.5 and
the subsection thereof entitled “Patent Litigation.” 

 Section 2.23 
 Insurance 
 (i) In Re ArthroCare Corporation
Securities Litigation, Case No. 1:08-cv-00574-SS (consolidated), U.S. District Court, Western District of Texas. In this action, Plaintiffs allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated
thereunder in a putative securities class action on behalf of certain purchasers of Company stock. Plaintiffs allege that the Company and certain officers and directors violated federal securities laws by issuing false and misleading financial
statements and making material misrepresentations regarding the Company’s internal controls, business, and financial results. Additionally, certain shareholders have alleged derivative claims on behalf of the Company that directors and officers
of the Company breached their fiduciary duties to shareholders based on similar acts. The cases have been consolidated, and the Plaintiffs have been ordered to file an Amended Consolidated Complaint. 
 (ii) In Re ArthroCare Corporation Derivative Litigation, Case No. D-1-GN-08-3484 (consolidated), Travis County District Court. In
this action, certain shareholders of the Company have alleged derivative claims on behalf of the Company that directors and officers of the Company breached their fiduciary duties to shareholders by failing to maintain adequate financial controls
over revenue recognition, allowing improper financial reporting, disseminating false financial statements, and engaging in insider trading. The case has been stayed until October 1, 2009 based on the consolidated federal securities and
derivative case.Registration Rights Agreement

 EXHIBIT 10.52 
 REGISTRATION RIGHTS AGREEMENT 
 This
Registration Rights Agreement (this “Agreement”) is made and entered into as of [—], 2009, by and among ArthroCare Corporation, a Delaware corporation (the
“Company”), and OEP AC Holdings, LLC, a Delaware limited liability company (the “Purchaser”). 
 WHEREAS,
the Purchaser has, pursuant to that certain Securities Purchase Agreement, dated as of August 14, 2009, between the Company and the Purchaser (the “Purchase Agreement”), agreed to purchase shares of the Company’s
Series A Convertible Preferred Stock, par value $0.001 per share (the “Preferred Stock”); 
 WHEREAS,
the shares of Preferred Stock are convertible into shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”); and 
 WHEREAS, it is a condition to the closing (the “Closing”) of the transactions contemplated by the Purchase Agreement that the Company and the Purchaser enter into this Agreement at
or prior to the Closing in order to grant the Purchaser certain registration rights as set forth herein. 
 NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows: 
 1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the
meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the respective meanings set forth in this Section 1: 
 “Affiliate” of any Person shall mean any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such Person. For purposes
of this definition, “control” when used with respect to any Person, has the meaning specified in Rule 12b-2 under the Exchange Act; and the terms “controlling” and “controlled” have meanings correlative to the
foregoing. 
 “automatic shelf registration statement” means an “automatic shelf registration
statement” as defined under Rule 405. 
 “Business Day” means a day that is a Monday, Tuesday,
Wednesday, Thursday or Friday and is not a day on which banking institutions in New York, New York generally are authorized or obligated by law, regulation or executive order to close. 
 “Commission” means the Securities and Exchange Commission or any other federal agency then administering the
Securities Act or Exchange Act. 
  

 1 

 “Effective Date” means the time and date that the initial
Registration Statements filed pursuant to either Section 2(a) or Section 2(b) hereof are first declared effective by the Commission or otherwise become effective. 
 “Effectiveness Date” means: 
 (a) with respect to the initial Registration Statement required to be filed pursuant to Section 2(a)
hereof, upon the expiration of the Lock-Up Period; 
 (b) with respect to the initial Registration Statement
required to be filed pursuant to Section 2(b) hereof, the 60th day following the filing of such initial Registration Statement; and 
 (c) with respect to any additional Registration Statements that may be required pursuant to Section 2(b) hereof, (i) if the Company is a WKSI, the date such additional Registration
Statement is filed or (ii) if the Company is not a WKSI, the earlier of: (x) the 90th day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required under
such Section and (y) the fifth Trading Day following the date on which the Company is notified by the Commission that such additional Registration Statement will not be reviewed or is no longer subject to further review and comments.

 “Effectiveness Period” means: 
 (a) with respect to the initial Registration Statement required to be filed pursuant to Section 2(a)
hereof, the period of time beginning on the Effective Date of such Registration Statement and continuing to the later of (i) the Effective Date of the Shelf or (ii) the date and time at which all Registrable Securities are sold or are
Freely Tradable; and 
 (b) with respect to any Registration Statements required to be filed pursuant to
Section 2(b) hereof, the period of time beginning on the Effective Date of such Registration Statement and continuing until the date and time at which all Registrable Securities are sold or are Freely Tradable. 
 “Electing Holders” means the Purchaser (if the Purchaser holds Registrable Securities) and any other Holder or
Holders (as applicable) which together hold no less than a majority of the then outstanding Registrable Securities. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Filing
Date” means: 
 (a) with respect to the initial Registration Statement required to be filed
pursuant to Section 2(a) hereof, the 60th day prior to the expiration of the Lock-Up Period; 
  

 2 

 (b) with respect to the initial Registration Statement required to be filed
pursuant to Section 2(b) hereof, the 30th day following the date on which the Company becomes eligible to file such Registration Statement; and 
 (c) with respect to any additional Registration Statements that may be required pursuant to Section 2(b)
hereof, the 30th day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required under such Section. 
 “Freely Tradable” means, with respect to any security, a security (a) that is eligible to be sold by the Holder
thereof without any volume or manner of sale restrictions under the Securities Act pursuant to Rule 144, (b) which bears no legends restricting the transfer thereof and (c) bears an unrestricted CUSIP number (if held in global form).

 “Holder” or “Holders” means the holder or holders, as the case may be, from
time to time of Registrable Securities. 
 “Indemnified Party” shall have the meaning set forth in
Section 5(c) hereof. 
 “Indemnifying Party” shall have the meaning set forth in
Section 5(c) hereof. 
 “Lock-Up Period” means the period of time beginning on the
date hereof through the date which is 365 days thereafter. 
 “Losses” shall have the meaning set forth
in Section 5(a) hereof. 
 “Person” means an individual or corporation, partnership,
trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 
 “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an
investigation or partial proceeding, such as a deposition), whether commenced or known to the Company to be threatened. 
 “Prospectus” means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective
registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a
Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 
 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock
and (ii) any securities issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend, stock split, recapitalization or other distribution with respect to, or in exchange for, or in
replacement of, the securities referenced in clause (i) above or this clause (ii); provided, however, that the term “Registrable Securities” shall exclude in all cases

  

 3 

 
any securities (i) sold or exchanged by a Person pursuant to an effective registration statement under the Securities Act or in compliance with Rule 144 or (ii) that are Freely Tradable
(it being understood that, for purposes of determining eligibility for resale under clause (ii) of this proviso, no securities held by the Purchaser shall be considered Freely Tradable to the extent the Purchaser reasonably determines that it
is an “affiliate” (as defined under Rule 144) of the Company). 
 “Registration Default” shall
have the meaning set forth in Section 2(d) hereof. 
 “Registration Default Date”
shall have the meaning set forth in Section 2(d) hereof. 
 “Registration Default
Period” shall have the meaning set forth in Section 2(d) hereof. 
 “Registration
Statement” means an initial registration statement which is required to register the resale of the Registrable Securities, and including the Prospectus, amendments and supplements to each such registration statement or Prospectus,
including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement. 
 “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 
 “Rule 405” means Rule 405 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter
adopted by the Commission having substantially the same effect as such Rule. 
 “Rule 415” means Rule
415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 
 “Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 
 “Rule 433” means Rule 433 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter
adopted by the Commission having substantially the same effect as such Rule. 
 “Securities Act” means
the Securities Act of 1933, as amended. 
 “Shelf” shall have the meaning set forth in
Section 2(b) hereof. 
 “Suspension Period” shall have the meaning set forth in
Section 2(c) hereof. 
  

 4 

 “Trading Day” means any Business Day on which the Common Stock is
traded, or able to be traded, on the principal national securities exchange or over-the-counter securities market on which the Common Stock is listed or admitted to trading. 
 “Trading Market” means the principal national securities exchange or over-the-counter securities market on which the
Common Stock is listed or admitted to trading. 
 “WKSI” means a “well-known seasoned issuer”
as defined under Rule 405. 
 2. Registration. 
 (a) The Company shall use its best efforts to become current in its reporting requirements pursuant to the Exchange Act. Upon becoming
current on its Exchange Act reporting requirements and in no event later than the Filing Date, the Company shall file with the Commission a Registration Statement covering the resale of all Registrable Securities. The Registration Statement
(i) shall be on Form S-1 and (ii) shall contain (except if otherwise requested by the Electing Holders or required pursuant to written comments received from the Commission upon a review of such Registration Statement) the “Plan of
Distribution” in substantially the form attached hereto as Annex A. The Company shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective or otherwise to become effective under the
Securities Act as soon as possible but, in any event, no later than the Effectiveness Date, and shall update the Registration Statement pursuant to Section 3(a)(iii) hereof during the Effectiveness Period applicable to this
Section 2(a). 
 (b) Within 30 days after the Company becomes eligible to file a Registration Statement on
Form S-3, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration Statement for an offering to be made on a
continuous basis pursuant to Rule 415 (the “Shelf”). The Registration Statement (i) shall be on Form S-3 and, if the Company is a WKSI as of the Filing Date, shall be an automatic shelf registration statement and
(ii) shall contain (except if otherwise requested by the Electing Holders or required pursuant to written comments received from the Commission upon a review of such Registration Statement) the “Plan of Distribution” in substantially
the form attached hereto as Annex A. The Company shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective or otherwise to become effective under the Securities Act as soon as possible
but, in any event, no later than the Effectiveness Date, and shall use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act during the Effectiveness Period applicable to this
Section 2(b). In addition, the Company shall, promptly and from time to time, file such additional Registration Statements to cover resales of any Registrable Securities which are not registered for resale pursuant to a
pre-existing Registration Statement no later than the Filing Date with respect thereto, and shall use its commercially reasonable efforts to cause such Registration Statement to be declared effective or otherwise to become effective under the
Securities Act as soon as practicable after the applicable Filing Date but, in any event, no later than the applicable Effectiveness Date, and shall use its commercially reasonable efforts to keep the Registration Statement continuously effective
under the Securities Act at all times during the Effectiveness Period applicable to this Section 2(b). 
  

 5 

 (c) Notwithstanding anything to the contrary in Section 2(a) or
Section 2(b) hereof, upon notice to the Holders, the Company may suspend the use or the effectiveness of the Registration Statement, or extend the time period in which it is required to file the Registration Statement, for up to
75 days in the aggregate in any 12-month period (a “Suspension Period”) if the Board of Directors of the Company determines, in its reasonable and good faith opinion, that the occurrence or existence of any
pending material corporate development makes such suspension appropriate because it would be materially detrimental to the Company for the registration to proceed at such time. In the event the Company exercises its rights under the preceding
sentence, the Holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the Prospectus relating to such Registration Statement in connection with any sale or offer to sell Registrable Securities. The
Company shall (i) use its commercially reasonable efforts to ensure that the use of such Registration Statement may be resumed as soon as such suspension is no longer appropriate and (ii) promptly notify the Holders when the Registration
Statement may once again be used or is effective. The Company shall not be permitted to deliver a notice of suspension, nor exercise its rights of suspension under this Section, more than twice during any 12-month period. 
 (d) If: (i) any Registration Statement is not filed on or prior to its Filing Date (it being understood that if the Company files a
Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a)(i) hereof, the Company shall not be deemed to have satisfied this clause (i)), (ii) a
Registration Statement is not declared effective by the Commission or does not otherwise become effective on or prior to its required Effectiveness Date, (iii) the Company fails to file with the Commission a request for acceleration in
accordance with Rule 461 promulgated by the Commission under the Securities Act within five Trading Days of the date on which the Company is notified (orally or in writing, whichever is earlier) by the Commission that a Registration Statement will
not be reviewed or is not subject to further review, or (iv) after its Effective Date, such Registration Statement ceases for any reason to be effective and available to the Holders as to all Registrable Securities to which it is required to
cover at any time prior to the expiration of the Effectiveness Period (in each case, except as specifically permitted herein with respect to any applicable Suspension Period) (any such failure or breach being referred to as a
“Registration Default,” and for purposes of clauses (i) or (ii) the date on which such Registration Default occurs, and for purposes of clause (iii) the date on which such five Trading Day period is exceeded
and for purposes of clause (iv) the date on which the Registration Statement ceases to be effective and available, being referred to as the “Registration Default Date” and each period from and including the Registration
Default Date during which a Registration Default has occurred and is continuing, a “Registration Default Period”), then, during the Registration Default Period, as liquidated damages and not as penalty and as the exclusive
remedy as to damages, in addition to any other equitable rights available to the Holders (including, without limitation, pursuant to Section 7(a) hereof), the Company shall pay in cash a special payment (collectively,
“Special Payments”) to Holders (x) in respect of each share of Preferred Stock that is convertible into a Registrable Security, in an amount equal to 2.00% per annum of the accrued liquidation preference of such
share of Preferred Stock and each additional share of Preferred Stock that would have otherwise been paid to the holder of such Preferred Stock from and including the immediately preceding dividend payment date to September 30, 2014, and
(y) in respect of each share of Common Stock issued upon conversion of Preferred Stock that is a Registrable Security, in an amount equal to 2.00% per annum of the quotient of (i) the accrued liquidation preference of the share of
Preferred Stock at the time of its conversion, divided by (ii) the

  

 6 

 
number of shares of Common Stock issued upon conversion of such share of Preferred Stock. Special Payments shall accrue from the applicable Registration Default Date until all Registration
Defaults have been cured, and shall be payable quarterly in arrears on each January 1, April 1, July 1 and October 1 following the applicable Registration Default Date to the record holder of the applicable security on
the date that is 15 days prior to such payment date, until paid in full. Special Payments payable in respect of any Registration Default Period shall be computed on the basis of a 360-day year consisting of twelve 30-day months. Special Payments
shall be payable only with respect to a single Registration Default at any given time, notwithstanding the fact that multiple Registration Defaults may have occurred and be continuing. 
 (e) The registration rights granted under this Section 2 shall automatically terminate as of the date and time at which
all Registrable Securities are Freely Tradable. 
 (f) Piggy-Back Registrations. If at any time during the Effectiveness
Period the Company shall determine to prepare and file with the Commission a Registration Statement relating to an offering of any of its equity securities for its own account or the account of others under the Securities Act, other than on Form S-4
or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with
stock option or other employee benefit plans, then the Company shall send to each Holder not then eligible to sell all of their Registrable Securities under Rule 144 in a three-month period, written notice of such determination and if, within 20
days after receipt of such notice, any such Holder shall so request in writing, the Company shall include in such Registration Statement all or any part of such Registrable Securities such Holder requests to be registered. Notwithstanding the
foregoing, in the event that, in connection with any underwritten public offering, the managing underwriter(s) thereof shall impose a limitation on the number of shares of Common Stock which may be included in the Registration Statement because, in
such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the
Registrable Securities with respect to which such Holder has requested inclusion hereunder as the underwriter shall permit; provided, however, that (i) the Company shall not exclude any Registrable Securities unless the Company
has first excluded all outstanding securities, the holders of which are not contractually entitled to inclusion of such securities in such Registration Statement or are not contractually entitled to pro rata inclusion with the Registrable Securities
and (ii) after giving effect to the immediately preceding proviso, any such exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities and the holders of other securities having the
contractual right to inclusion of their securities in such Registration Statement by reason of demand registration rights, in proportion to the number of Registrable Securities or other securities, as applicable, sought to be included by each such
Holder or such other holder. If an offering in connection with which a Holder is entitled to registration under this Section 2 is an underwritten offering, then each Holder whose Registrable Securities are included in such
Registration Statement shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in an underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same
terms and conditions as other shares of Common Stock included in such underwritten offering and shall enter into an underwriting agreement in a customary form

  

 7 

 
and substance reasonably satisfactory to the Company and the underwriter or underwriters. Upon the effectiveness of the Registration Statement for which piggy-back registration has been provided
in this Section 2, any Special Payments payable to a Holder whose Common Shares are included in such Registration Statement shall terminate and no longer be payable after such date (it being understood that any unpaid Special
Payments accrued prior to such date shall remain due and payable in accordance with Section 2(d) hereof). 
 3. Registration Procedures. 
 (a) In connection with the Company’s registration obligations hereunder, the
Company shall: 
 (i) Not less than five Trading Days prior to the filing of a Registration Statement or any
related Prospectus or any amendment or supplement thereto, the Company shall furnish to the Holders copies of all such documents proposed to be filed, which documents (other than those incorporated by reference) will be subject to the review of such
Holders. Except as required by law, the Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Electing Holders shall reasonably object in good faith. 
 (ii) Use commercially reasonable efforts to (i) prepare and file with the Commission such amendments, including
post-effective amendments, to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for its
Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to be amended or
supplemented by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424; and (iii) respond as promptly as reasonably possible, and in any event within ten Trading Days, to any comments received
from the Commission with respect to each Registration Statement or any amendment thereto and, as promptly as reasonably possible provide the Holders true and complete copies of all correspondence from and to the Commission relating to such
Registration Statement that pertains to the Holders as Selling Stockholders but not any comments that would result in the disclosure to the Holders of material and non-public information concerning the Company. 
 (iii) Following the expiration of the Lock-Up Period and upon request by the Electing Holders, the Company shall update as
promptly as reasonably possible the Registration Statement required pursuant to Section 2(a) hereof until the Shelf is declared effective; provided that the Company shall not be required to so update such Registration
Statement more than two times per any 365-day period. 
 (iv) Comply in all material respects with the
provisions of the Securities Act and the Exchange Act with respect to each Registration Statement and the disposition of all Registrable Securities covered by each Registration Statement. 
  

 8 

 (v) Notify the Holders as promptly as reasonably possible (and, in the case
of clause (i)(A) below, not less than five Trading Days prior to such filing) and (if requested by any such Holder) confirm such notice in writing no later than one Trading Day following the day: (i)(A) when a Prospectus or any Prospectus supplement
or post-effective amendment to a Registration Statement is proposed to be filed; (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in
writing on such Registration Statement (in which case the Company shall provide true and complete copies thereof and all written responses thereto to each of the Holders that pertain to the Holders as a Selling Stockholder or to the Plan of
Distribution, but not information which the Company reasonably believes would constitute material and non-public information covering the Company); and (C) with respect to each Registration Statement or any post-effective amendment, when the
same has been declared effective; (ii) of any request by the Commission or any other Federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains to
the Holders as Selling Stockholders or the Plan of Distribution; (iii) of the issuance by the Commission of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the
initiation of any Proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any
jurisdiction, or the initiation or threatening of any Proceeding for such purpose; and (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion
therein or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration Statement,
Prospectus or other documents so that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 (vi) Use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or
exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment. 
 (vii) Furnish to each Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto and all exhibits to the extent requested by such Holder (including those
incorporated by reference) promptly after the filing of such documents with the Commission; provided, that the Company shall have no obligation to provide any document pursuant to this clause that is available on the EDGAR system. 

(viii) Promptly deliver to each Holder, without charge, as many copies of each Prospectus or Prospectuses (including each
form of prospectus) and each amendment or supplement thereto as such Holder may reasonably request. The Company

  

 9 

 
hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities
covered by such Prospectus and any amendment or supplement thereto. 
 (ix) Prior to any public offering of
Registrable Securities, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from such registration or qualification) of such
Registrable Securities for offer and sale under the securities or Blue Sky laws of those jurisdictions within the United States as any Holder reasonably requests in writing and to keep each such registration or qualification (or exemption therefrom)
effective during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by the Registration Statements; provided, that
the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified or subject the Company to any material tax in any such jurisdiction where it is not then so subject. 
 (x) Cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such
denominations and registered in such names as any such Holders may request. In connection therewith, if required by the Company’s transfer agent, the Company shall, promptly after the effectiveness of a Registration Statement, cause an opinion
of counsel as to the effectiveness of the Registration Statement to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates and directions required by the transfer agent which authorize and direct
the transfer agent to issue such Registrable Securities without legend upon sale by the holder of such shares of Registrable Securities under the Registration Statement. 
 (xi) Upon the occurrence of any event contemplated by clause (v) of Section 3(a)(v) hereof, as
promptly as reasonably possible, prepare a supplement or amendment, including a post-effective amendment, if required by applicable law, to the affected Registration Statement or a supplement to the related Prospectus or any document incorporated or
deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 (xii) In the event the Holders seek to complete an underwritten offering, for a reasonable period prior to the filing of any Registration Statement, and throughout the Effectiveness Period, make available
upon reasonable notice at the Company’s principal place of business or such other reasonable place for inspection by the Holders (and the managing underwriter or underwriters selected in accordance with Section 3(c) hereof),
such financial and other information and books and records of the

  

 10 

 
Company, and cause the officers, employees, counsel and independent certified public accountants of the Company to respond to such inquiries, as shall be reasonably necessary (and in the case of
counsel, not violate any attorney-client privilege, in such counsel’s reasonable belief), in the judgment of legal counsel to the Holders (and legal counsel for such managing underwriter or underwriters), to conduct a reasonable investigation
within the meaning of Section 11 of the Securities Act; provided, however, that the foregoing inspection and information gathering on behalf of the Holders (and any managing underwriter or underwriters) shall be conducted
by legal counsel to the Holders (and legal counsel to such managing underwriter or underwriters); and provided, further that each such party shall be required to maintain in confidence and not to disclose to any other Person any
information or records reasonably designated by the Company as being confidential, until such time as (A) such information becomes a matter of public record (whether by virtue of its inclusion in the Registration Statement or in any other
manner other than through the release of such information by any Person afforded access to such information pursuant hereto), or (B) such Person shall be required so to disclose such information pursuant to a subpoena or order of any court or
other governmental agency or body having jurisdiction over the matter (subject to the requirements of such order, and only after such Person shall have given the Company prompt prior written notice of such requirement). 
 (xiii) Use its best efforts to list such Registrable Securities on any national securities exchange on which the Common
Stock is then listed, if such Registrable Securities are not already so listed and if such listing is then permitted under the rules of such exchange. 
 (b) In connection with the filing of any Registration Statement, the Company may require each selling Holder to furnish to the Company a certified statement as to the securities of the Company (including
shares of Common Stock and Preferred Stock) beneficially owned by such Holder and any Affiliate thereof; provided, however, the Purchaser shall not be required to furnish such statement in connection with the initial Registration
Statement if the Purchaser own all of the outstanding Preferred Stock as of the initial Filing Date. 
 (c) The Holders may
distribute the Registrable Securities by means of an underwritten offering; provided that (a) the Electing Holders provide written notice to the Company of their intention to distribute Registrable Securities by means of an underwritten
offering, (b) the managing underwriter or underwriters thereof shall be designated by the Electing Holders (provided, however, that such designated managing underwriter or underwriters shall be reasonably acceptable to the
Company), (c) each Holder participating in such underwritten offering agrees to sell such Holder’s Registrable Securities on the basis provided in any underwriting arrangements approved by the persons entitled to select the managing
underwriter or underwriters hereunder and (d) each Holder participating in such underwritten offering completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required
under the terms of such underwriting arrangements. The Company hereby agrees with each Holder that, in connection with any underwritten offering in accordance with the terms hereof, it will negotiate in good faith and execute all indemnities,
underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements, including using all commercially reasonable efforts to procure customary legal opinions and auditor “comfort” letters.

  

 11 

 4. Registration Expenses. All fees and expenses incident to the Company’s
performance of or compliance with its obligations under this Agreement (excluding any underwriting discounts and selling commissions, but including all legal fees and expenses of one legal counsel to the Holders) shall be borne by the Company
whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without
limitation, fees and expenses (A) with respect to filings required to be made with the Trading Market, and (B) in compliance with applicable state securities or Blue Sky laws), (ii) printing expenses (including, without limitation,
expenses of printing certificates for Registrable Securities and of printing prospectuses if the printing of prospectuses is reasonably requested by the Holders of a majority of the Registrable Securities included in the Registration Statement),
(iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other
Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of
the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in
connection with the listing of the Registrable Securities on any securities exchange as required hereunder. 
 5.
Indemnification. 
 (a) Indemnification by the Company. The Company shall, notwithstanding any termination of
this Agreement, indemnify and hold harmless each Holder and each underwriter, broker-dealer or selling agent, if any, which facilitates the disposition of Registrable Securities, the officers, directors, agents, partners, members, stockholders and
employees of each of them, each Person who controls any such Holder, underwriter, broker-dealer or selling agent (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, agents
and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs of preparation and reasonable
attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus or any
form of prospectus (including, without limitation, any “issuer free writing prospectus” as defined in Rule 433) or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or
alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus (including, without limitation, any “issuer free writing prospectus” as
defined in Rule 433) or supplement thereto, in light of the circumstances under which they were made) not misleading, except (and only) to the extent that such untrue statements, alleged untrue statements, omissions or alleged omissions are based
solely upon information regarding such Holder, underwriter, broker-dealer or selling agent furnished in writing to the Company by such Person expressly for use therein pursuant to Section 3(b) hereof.

  

 12 

 
The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of which the Company is aware in connection with the transactions contemplated by this
Agreement. 
 (b) Indemnification by Holders. Each Holder shall, notwithstanding any termination of this Agreement,
severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, agents or employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising solely out of or based solely upon any untrue statement of a
material fact contained in any Registration Statement, any Prospectus, or any form of prospectus (including, without limitation, any “issuer free writing prospectus” as defined in Rule 433), or in any amendment or supplement thereto, or
arising solely out of or based solely upon any omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, or any form of prospectus (including, without limitation, any
“issuer free writing prospectus” as defined in Rule 433) or supplement thereto, in light of the circumstances under which they were made) not misleading, to the extent, but only to the extent, that such untrue statements or omissions are
based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net
proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation. 
 (c) Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly
notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the
Indemnified Party and the payment of all fees and expenses incurred in connection with the defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or
liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have
proximately and materially adversely prejudiced the Indemnifying Party. 
 An Indemnified Party shall have the right to employ
separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in
writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or
(3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely
to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the
Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the

  

 13 

 
Indemnifying Party); provided, that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified
Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written
consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such Proceeding. 
 All fees and expenses of the Indemnified Party (including, without
limitation, reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, promptly
upon receipt of written notice thereof by the Indemnifying Party (regardless of whether it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder); provided, that the Indemnifying Party may require
such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder. 
 (d) Contribution. If a claim for indemnification under Section 5(a) or Section 5(b) hereof is
unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such
Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or
omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity
to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section 5(c) hereof, any reasonable
attorneys’ fees or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was
available to such party in accordance with its terms. 
 The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding
paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Holder from the
sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
  

 14 

 The indemnity and contribution agreements contained in this Section 5 are
in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Purchase Agreement. 
 6. Facilitation of Sales Pursuant to Rule 144. On and after the expiration of the Lock-Up Period, to the extent it shall be required
to do so under the Exchange Act, the Company shall timely file the reports required to be filed by it under the Exchange Act or the Securities Act (including the reports under Sections 13 and 15(d) of the Exchange Act referred to in
subparagraph (c)(1) of Rule 144), and shall take such further action as any Holder may reasonably request, all to the extent required from time to time to enable the Holders to sell Registrable Securities without registration under the
Securities Act within the limitations of the exemption provided by Rule 144. Upon the request of any Holder in connection with that holder’s sale pursuant to Rule 144, the Company shall deliver to such Holder a written statement as to
whether it has complied with such requirements. 
 7. Miscellaneous. 
 (a) Remedies. In the event of a breach by the Company or by a Holder, of any of their obligations under this Agreement, each Holder
or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be entitled to seek specific performance of its rights under this
Agreement. The Company and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the
event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate. 
 (b) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of Registrable
Securities pursuant to a Registration Statement. 
 (c) Discontinued Disposition. Each Holder agrees by its
acquisition of such Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(a)(v) hereof, such Holder shall forthwith discontinue disposition of such
Registrable Securities under the Registration Statement until such Holder’s receipt of the copies of the supplemented Prospectus and/or amended Registration Statement or until it is advised in writing by the Company that the use of the
applicable Prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The Company
may provide appropriate stop orders to enforce the provisions of this paragraph. 
  

 15 

 (d) Amendments and Waivers. No provision of this Agreement may be waived or amended
except in a written instrument signed by the Company and the Electing Holders. The Company shall provide prior notice to all Holders of any proposed waiver or amendment. No waiver of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to
exercise any right hereunder in any manner impair the exercise of any such right. 
 (e) Notices. Any and all notices or
other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via
facsimile or electronic mail as specified in this Section prior to 5:00 p.m. (New York time) on a Business Day, (ii) the Business Day after the date of transmission, if such notice or communication is delivered via facsimile or electronic mail
as specified in this Agreement later than 5:00 p.m. (New York time) on any date and earlier than 11:59 p.m. (New York time) on such date, (iii) the Business Day following the date of mailing, if sent by nationally recognized overnight courier
service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows: 
  

			
	If to the Company:	  	ArthroCare Corporation
		  	 7500 Rialto Boulevard
 Building Two
 Austin, TX 78735
 Attention: Richard Rew, Senior VP and General Counsel
 Facsimile: (512) 391-3901
 Email: richard.rew@arthrocare.com

		
	With a copy to:	  	Latham & Watkins LLP
		  	 233 S. Wacker Drive
 Suite
5800
 Chicago, IL 60606
 Attention:
Richard Meller
 Facsimile: (312) 993-9767
 Email: richard.meller@lw.com

		
	If to the Purchaser:	  	 OEP AC Holdings, LLC
 c/o
One Equity Partners III, L.P.
 320 Park Avenue, 18th Floor
 New
York, NY 10022
 Attention: Gregory A. Belinfanti and Christian Ahrens
 Facsimile: (212) 277-1533
 Email: gregory.a.belinfanti@oneequity.com
             chris.ahrens@oneequity.com

  

 16 

			
	With a copy to:	  	Dechert LLP
		  	1095 Avenue of the Americas
		  	New York, NY 10036
		  	Attention: Derek M. Winokur
		  	Facsimile: (212) 698-3599
		  	Email: derek.winokur@dechert.com
		
	 If to any other Person
 who is
then a
 registered Holder:
	  	To the address of such Holder as it appears in the stock transfer books of the Company

 or such other address as may be designated in writing hereafter, in the same manner, by such Person.

 (f) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and
permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign its rights or obligations hereunder without the prior written consent of the Electing Holders. 
 (g) Execution and Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed shall be
deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile or electronic mail transmission, such signature shall create a valid binding
obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such signature delivered by facsimile or electronic mail transmission were the original thereof. 
 (h) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York.

 (i) Submission to Jurisdiction. The Company and the Purchaser each irrevocably and unconditionally submits, for itself
and its property, to the exclusive jurisdiction of the courts of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action
or proceeding arising out of or relating to this Agreement, or for the recognition or enforcement of any judgment in connection herewith, and each of the parties hereto irrevocably and unconditionally agrees that all claims in respect of any such
action or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding
shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 
 (j) Waiver of Venue. The parties hereto each irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, (i) any objection that it may now or hereafter have to the laying of venue of any action or
proceeding arising out of or relating to this Agreement in any court referred to in Section 7(i) hereof and (ii) the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

  

 17 

 (k) Cumulative Remedies. The remedies provided herein are cumulative and not
exclusive of any remedies provided by law. 
 (l) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be
affected, impaired or invalidated, and the parties hereto shall use their reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or
restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid,
illegal, void or unenforceable. 
 (m) Entire Agreement. This Agreement constitutes the entire agreement between the
parties hereto pertaining to the subject matter hereof, and supersedes all other prior agreements and understandings, both written and oral, between the parties, with respect to the subject matter hereof. 
 (n) Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the
meaning hereof. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 18 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above. 
  

			
	ARTHROCARE CORPORATION
		
	By:	 	  

	Name:	 	David Fitzgerald
	Title:	 	Acting President and Chief Executive Officer

 SIGNATURE PAGE TO ARTHROCARE CORPORATION 
 REGISTRATION RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above. 
  

			
	OEP AC HOLDINGS, LLC
		
	By:	 	 /s/    Christian Ahrens

		 	Name: Christian Ahrens
		 	Title: Vice President and Treasurer

 SIGNATURE PAGE TO ARTHROCARE CORPORATION 
 REGISTRATION RIGHTS AGREEMENT 

 ANNEX A 
 PLAN OF DISTRIBUTION 
 The Selling Stockholders and
any of their pledgees, donees, transferees, assignees or other successors-in-interest may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of Common Stock or Preferred Stock (“Shares”) or interests in
Shares on any stock exchange, market or trading facility on which the Shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing
market price, at varying prices determined at the time of sale, or at negotiated prices, except to the extent limited by Rule 415(a)(4) promulgated under the Securities Act. The Selling Stockholders may use one or more of the following methods when
disposing of the Shares or interests therein: 
  

	 	•	 	 ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	 	 block trades in which the broker-dealer will attempt to sell the Shares as agent but may position and resell a portion of the block as principal to
facilitate the transaction; 

  

	 	•	 	 purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	 	 an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	 	 privately negotiated transactions; 

  

	 	•	 	 through collared hedging transactions, whether through an options exchange or otherwise; 

  

	 	•	 	 broker-dealers may agree with the Selling Stockholders to sell a specified number of such Shares at a stipulated price per share;

  

	 	•	 	 a combination of any such methods of disposition; and 

  

	 	•	 	 any other method permitted pursuant to applicable law. 

 The Selling Stockholders may also sell Shares under Rule 144 promulgated under the Securities Act, if available, rather than under this prospectus. 
 Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of Shares, from the purchaser) in amounts to be negotiated. The Selling Stockholders do not expect these commissions and discounts to
exceed what is customary in the types of transactions involved. 
  

 1 

 The Selling Stockholders may from time to time pledge or grant a security interest in some
or all of the Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell Shares from time to time under this prospectus, or under an amendment to this prospectus
under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. 
 Upon the Company being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer
for the sale of Shares through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the
Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Shares involved, (iii) the price at which such Shares were sold, (iv) the commissions paid or
discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi) other
facts material to the transaction. In addition, upon the Company being notified in writing by a Selling Stockholder that a donee or pledge intends to sell more than 500 Shares, a supplement to this prospectus will be filed if then required in
accordance with applicable securities law. 
 The Selling Stockholders also may transfer the Shares in other circumstances, in
which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 
 In connection with the sale of Shares or interests in Shares, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in
short sales of the Common Stock in the course of hedging the positions they assume. The Selling Stockholders may also loan or pledge the Common Stock to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of Shares offered by this
prospectus, which Shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 
 The Selling Stockholders may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to
third parties in privately negotiated transactions, in each case in collared hedging transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this
prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by the Selling Stockholders or borrowed from the Selling Stockholders or others to settle those sales or to
close out any related open borrowings of stock, and may use securities received from the Selling Stockholders in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an
underwriter and, if not identified in this prospectus, will be identified in the applicable prospectus supplement (or a post-effective amendment). 
  

 2 

 The Company has advised the Selling Stockholders that they are required to comply with
Regulation M promulgated under the Exchange Act during such time as they may be engaged in a distribution of the Shares. The foregoing may affect the marketability of the Shares. 
 The Company is required to pay all fees and expenses incident to the registration of the Shares. The Company has agreed to indemnify the
Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act or otherwise. 
 The Company has agreed with the Selling Stockholders to keep the registration statement of which this prospectus constitutes a part effective until such time as all of the securities covered by this
prospectus (i) have been disposed of pursuant to and in accordance with the registration statement or in compliance with Rule 144 promulgated under the Securities Act or (ii) are eligible to be sold by the holder thereof without any volume
or manner of sale restrictions pursuant to Rule 144 promulgated under the Securities Act, bear no legend restricting the transfer thereof and bear an unrestricted CUSIP number (if held in global form). 
  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]